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Abstract: As life expectancy is increasing, elderly patients are evaluated more frequently for resection
of benign or malignant pancreatic lesions. However, the impact of age on postoperative morbidity,
mortality, and treatment costs in octogenarian patients (≥80 years) undergoing major pancreatic
surgery needs further investigation. The clinicopathological data of patients who underwent pan-
creatic surgery between January 2015 and March 2019 in a major hepatopancreatobiliary center in
Switzerland were assessed. Postoperative outcomes and hospital costs of octogenarians and younger
patients were compared in univariate and multivariate regression analysis. During the study period,
346 patients underwent pancreatic resection. Pancreatoduodenectomy, distal pancreatectomy, total
pancreatectomy, and other procedures were performed in 54%, 20%, 13%, and 13% of patients,
respectively. The major postoperative morbidity rate and postoperative mortality rate were 25% and
3.5%, respectively. A total of 39 patients (11%) were ≥80 years old, and 307 patients were <80 years
old. The majority of octogenarians suffered from ductal adenocarcinoma, whereas among younger
patients, other indications for a pancreatic resection were predominant (ductal adenocarcinoma 64%
vs. 41%, p = 0.006). Age ≥80 was associated with more frequent postoperative medical (pulmonary,
cardiovascular) and surgical (high-grade pancreatic fistula, postoperative hemorrhage) complications.
Postoperative mortality was significantly higher in octogenarians (15.4% vs. 2%, p < 0.0001). This
finding may be explained by the higher rate of type C pancreatic fistula (13% vs. 5%), resulting
more frequently in postoperative hemorrhage (18% vs. 5%, p = 0.002) among patients ≥80 years
old. In the multivariate logistic regression analysis, patient age ≥80 years predicted postoperative
mortality independently of the tumor entity and surgical technique (p = 0.013, OR 6.71, 95% CI
[1.5–30.3]). Increased major postoperative morbidity was responsible for lower cost recovery in
octogenarians (94% vs. 102%, p = 0.046). In conclusion, patient age ≥80 years is associated with
increased postoperative medical and surgical morbidity after major pancreatic surgery leading to
lower cost recovery and a lower chance for successful resuscitation in patients requiring revisional
surgery for postoperative hemorrhage and/or pancreatic fistula. In octogenarian patients suffering
from pancreatic tumors, careful selection, and thorough prehabilitation is crucial to achieve the best
postoperative and long-term oncologic outcomes.
Keywords: pancreatic surgery; elderly; octogenarian; mortality; morbidity; cost recovery
1. Introduction
Pancreatic cancer is currently increasing, as is the aging population worldwide. The
≥80 years old population is expected to grow by a factor of four in the next four decades [1].
Pancreatic surgery has significantly evolved over the past decades. Surgical techniques
for the pancreas have also been gradually modified to achieve better functional results [2].
Minimally invasive surgery has been introduced in order to minimize surgical trauma [3].
Successive advances in surgical and perioperative management made pancreatic surgery
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safer and significantly reduced postoperative mortality and morbidity [4,5]. As a result
of the widened technical possibilities and improved postoperative outcomes in pancre-
atic surgery, the indication for pancreatic resection has been extended to benign lesions,
such as intraductal papillary mucinous neoplasm (IPMN) and chronic pancreatitis [2,6,7].
Moreover, diagnostic tools, such as computed tomography (CT) and magnetic-resonance
imaging (MRI), have been increasingly used with enhanced quality and are partially re-
sponsible for the growing number of newly found pancreatic lesions [8]. For all these
reasons, the number of pancreatic resections performed continues to grow.
Additionally, with the increasing aging of the population, more diagnoses of pancreatic
pathologies requiring surgery have been identified in the older population, and even more
are expected to be diagnosed in the near future [9–11]. Innovations in surgical, endoscopic,
and anesthesiologic treatment, as well as the establishment of modern neoadjuvant systemic
therapies, have enabled more patients with advanced age diagnosed with pancreatic ductal
adenocarcinoma (PDAC) to undergo surgery. Thus, elderly patients previously considered
as unresectable, due to relevant comorbidities or advanced disease are currently more
frequently selected as eligible candidates for curative resection [12].
Previous studies investigating age-associated postoperative morbidity and mortality
in pancreatic surgery have demonstrated conflicting results. Some single-center studies
did not find age as a negative prognostic factor for postoperative outcomes [8,9,13]. On the
other hand, population-based studies found a negative association between older age and
postoperative morbidity and mortality following pancreatic surgery [11,14,15].
Patient age has been associated with higher postoperative complication rates, and
surgical morbidity has been related to increased treatment costs in recent studies focusing
on pancreatic resections [16,17]. Political and hospital administration, as well as health
insurance companies, lay great importance on this matter and demand the best possible
cost-effectiveness.
As more elderly patients are diagnosed with pancreatic pathologies requiring resec-
tion, surgeons need to evaluate operability, taking into account multiple factors, such as
concomitant comorbidities, expected perioperative morbidity and mortality, and estimated
long-term prognosis in order to optimize the selection of appropriate surgical candidates.
We hypothesized that postoperative morbidity and mortality following pancreatic surgery
is higher in patients ≥80 years old as compared to younger patients. Consequently, treat-
ment costs are also expected to be higher in the elderly population. Therefore, the aim of
this study was to compare postoperative morbidity, mortality, and treatment cost recovery
in patients younger and older than80 years undergoing pancreatic resection in a major
hepatopancreatobiliary center in Switzerland.
2. Material and Methods
2.1. Patient Inclusion Criteria
This study was approved by the Cantonal Ethical Committee of Bern (2019-01171). The
anonymity of the patients in this study was preserved at any time during data acquisition
and analysis. In this retrospective study [18], all consecutive patients who underwent
pancreatic resection for benign and malignant pancreatic lesions between January 2015
and March 2019 at the Department of Visceral Surgery und Medicine, Inselspital, Bern
University Hospital were included. Patients < 18 years old were excluded from the analysis.
2.2. Preoperative Management
The standard preoperative patient evaluation included medical history, physical
examination, serum laboratory tests, imaging studies, and an anesthesia evaluation. In the
case of malignant tumor, the location and extent of tumor burden, as well as the presence
of lymph node or distant metastases, were determined by cross-sectional imaging, such as
contrast-enhanced CT and/or MRI.
In the case of obstructive jaundice, some patients underwent bile decompression
using bile duct stents during endoscopic retrograde cholangiopancreatography, endoscopic
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hepaticogastrostomy, or percutanous transhepatic drainage. The decision to proceed with
a bile decompression was individually made according to the duration and extent of
cholestasis and the general condition of the patient.
All patients presenting with a malignant tumor were preoperatively discussed at
our interdisciplinary tumor board, including pancreatic surgeons, medical oncologists,
radiation therapists, and specialized radiologists. Tumor resectability was assessed, and
an individualized course of treatment was established for each patient. In patients with
borderline resectable or locally-advanced adenocarcinoma, preoperative chemotherapy
was recommended, as also described by others [19].
Surgical indication for patients ≥80 years old with pancreatic pathology did not differ
from that of younger patients. Medical preconditions and nutritional status [20] were thor-
oughly evaluated in all patients to identify patients with increased risk for postoperative
medical and surgical complications. In the case of relevant comorbidities or nutritional
deficiency, preoperative interventions and nutritional prehabilitation were performed to
optimize the patients’ status prior to surgery. Extensive preoperative counseling was
performed, especially with octogenarians, in order to inform patients in detail regarding
potential postoperative complications and complicated postoperative clinical course.
2.3. Surgical Procedure
Pancreatic resections included pancreatoduodenectomy (PD), distal pancreatectomy,
total pancreatectomy, duodenum-preserving pancreatic head resection, and segmental
pancreatic resection. Necrosectomies for pancreatitis were excluded. Resections were
either performed using a conventional open technique or a laparoscopic-assisted procedure
beginning in 2017. Following an upper transverse laparotomy or diagnostic laparoscopy,
previously undiagnosed tumor spread into the peritoneum or the liver was ruled out.
Classic Kausch-Whipple or pylorus-preserving PD was performed to remove the pancreatic
head as previously described [21]. Reconstruction was performed by pancreatojejunostomy
using a dissected jejunal loop, end-to-side hepaticojejunostomy, and gastrojejunostomy
to re-establish the gastrointestinal passage. Perianastomotic drains were intraoperatively
placed to monitor pancreatic fistula, anastomotic leak, and postoperative hemorrhage. In
the case of tumor involvement of the portal vein/superior mesenteric vein or superior
mesenteric artery, vessel resection, and reconstruction either with anastomosis or graft
interposition were performed. Irreversible electroporation (IRE) was used for margin
accentuation in patients with a borderline resectable disease to the hepatic artery, celiac
trunk, or superior mesenteric artery [22,23].
2.4. Postoperative Management
After surgery, all patients were monitored for postoperative complications. Remark-
able discharge from perianastomotic drains or persistently increased bilirubin, or lipase
levels in drained fluids were indicators for biliary leak and pancreatic fistula, respectively.
The criteria of the International Study Group on Pancreatic Fistula (ISGPS) were used for
classifying postoperative pancreatic fistulas (POPF) in three severity grades (biochemical
leak or A, B, and C), and patients were treated accordingly [24]. Further complications
were documented, such as postoperative hemorrhage (defined as hemodynamic- and
hemoglobin-relevant bleeding [25]), wound infection (defined as surgical site infection [26]),
pulmonary (including pneumonia and pleural effusions), cardiovascular (including hemo-
dynamic instability, cardiac insufficiency, myocardial infarction), and renal complications
(including renal failure) [27].
Postoperative morbidity was defined as any complication within 90 days after the
surgical procedure and was classified according to a standardized classification [28]. Post-
operative complications ≥ grade 3 were defined as major morbidity. The postoperative
mortality rate was defined as the fraction of patients suffering any complication within
90 days following surgery leading to death.
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Postoperative chemotherapy and radiotherapy were administered in patients based
on recommendations of the interdisciplinary tumor board.
2.5. Statistical Analysis
The primary endpoint of this study was the comparison between patients ≥80 years
old vs. patients <80 years regarding postoperative 90-day mortality. Secondary endpoints
were the comparison of the two groups in regard to postoperative 90-day morbidity,
cost recovery (CR), defined as the ratio treatment costs/proceeds in percent according to
the Swiss diagnosis-related groups (DRG) reimbursement system, and overall-survival
(OS). These objectives were investigated in the entire cohort of patients who underwent
pancreatic resection during the study period, as well as in subgroups of patients undergoing
PD, and patients undergoing resection for PDAC.
Quantitative and qualitative variables were expressed as medians (range) and fre-
quencies. The Chi-square or Fisher’s exact test, and the Mann-Whitney U test were used to
compare categorical and continuous variables, as appropriate.
To identify factors associated with postoperative mortality after pancreatic resection,
clinicopathological variables were analyzed in univariate analysis. In the subsequent
multivariate analysis, all factors with p value < 0.05 in univariate analysis were entered in
a logistic regression model to identify independent predictors for postoperative mortality.
Using the Kaplan-Meier method, OS was calculated for patients with PDAC from the
date of surgical procedure to the date of death or last follow-up. Log-rank test was used to
compare OS between patients ≥80 years old vs. patients <80 years old.
p values < 0.05 were considered statistically significant. For statistical analysis, SPSS
software package, version 25, by IBM (Armonk, NY, USA) was used.
3. Results
3.1. Patient Characteristics and Postoperative Outcomes in the Entire Cohort
From January 2015 to March 2019, 346 patients underwent pancreatic resection, 307 pa-
tients were <80 years old, and 39 patients (11%) were ≥80 years old. In-depth information
on the entire cohort and the treatment is given in Table 1. Pancreatic pathologies, including
PDAC, periampullary cancers, cystic lesions, neuroendocrine tumors, and chronic pancre-
atitis, were not significantly differently distributed between patients ≥80 years old and
patients <80 years old (p = 0.127). The major postoperative morbidity rate and 90-day post-
operative mortality rate for the entire cohort were 25% and 3.5%, respectively. POPF type C,
postoperative hemorrhage, pulmonary and cardiovascular complications were significantly
higher among patients ≥80 years old. Postoperative mortality was also significantly higher
among patients ≥80 years old (15% vs. 2%, p < 0.0001). Cost recovery calculation revealed
unfavorable outcomes for the older patients (94% (46–172) vs. 102% (38–233), p = 0.046).
The median hospital costs in our cohort were 38’185 (15’763–176’318) CHF.
Table 1. Comparison of clinicopathological characteristics of 346 patients undergoing pancreatic surgery according to
patient age.




(n = 346) p Value
Gender, n (%) 0.106
Female 139 (45) 23 (59) 162 (47)
Male 168 (55) 16 (41) 184 (53)
cost recovery, %, median (range) 102 (38–233) 94 (46–172) 101 (38–233) 0.046
cardiovascular disease, n (%) 157 (51) 33 (85) 190 (55) <0.0001
Kidney disease, n (%) 41 (13) 13 (33) 53 (15) 0.001
Pulmonary disease, n (%) 71 (23) 8 (21) 79 (23) 0.714
Infectious disease, n (%) 11 (4) 1 (3) 12 (4) 0.743
Liver disease, n (%) 43 (14) 7 (18) 50 (15) 0.510
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Table 1. Cont.




(n = 346) p Value
Neurologic disease, n (%) 49 (16) 6 (15) 55 (16) 0.926
Diabetes, n (%) 73 (24) 11 (28) 84 (24) 0.544
Genetical alteration, n (%) 9 (3) 0 (0) 9 (3) 0.279
BMI, kg/m2, median (range) 24 (16–46) 24 (16–31) 24 (16–46) 0.167
BMI > 30, kg/m2, n (%) 48 (16) 4 (19) 52 (15) 0.376
Smoking, n (%) 131 (43) 3 (8) 134 (39) <0.0001
Alcohol consumption, n (%) 106 (35) 6 (15) 112 (32) 0.016
ASA status, n (%) 0.009
1 7 (2) 0 (0) 7 (2)
2 98 (32) 5 (13) 103 (30)
3 190 (62) 29 (74) 219 (63)
4 12 (4) 5 (13) 17 (5)
Resection type, n (%) 0.122
Pancreatoduodenectomy 159 (52) 26 (67) 185 (54)
Distal pancreatectomy 63 (21) 6 (15) 69 (20)
Total pancreatectomy 38 (12) 7 (18) 45 (13)
Enucleation 3 (1) 0 (0) 3 (1)
Duodenal-preserving resection 24 (8) 0 (0) 24 (7)
Segmental pancreatic resection 20 (6) 0 (0) 20 (5)
Operating time, h, median (range) 5.0 (1–10) 5.75 (3–9) 5.2 (1–10) 0.014
Vascular reconstruction, n (%) 0.638
none 240 (78) 28 (72) 268 (78)
venous 56 (19) 10 (26) 66 (19)
arterial 7 (2) 1 (2) 8 (2)
combined 4 (1) 0 (0) 4 (1)
Histologic type, n (%) 0.006
Adenocarcinoma 125 (41) 25 (64) 150 (43)
other 182 (59) 14 (36) 196 (57)
Pancreatic pathologies, n (%) 0.127
PDAC 125 (41) 25 (64) 150 (43)
periampullary malignancies 46 (15) 6 (16) 52 (15)
cystic lesions 64 (21) 5 (13) 69 (20)
neuroendocrine tumors 28 (9) 2(5) 30 (9)
chronic pancreatitis 44 (14) 1 (2) 45 (13)
Length of ICU stay, days, median (range) 1 (0–37) 1 (1–19) 1 (0–37) 0.065
Length of hospital stay, days, median (range) 13 (2–87) 13 (3–66) 13 (2–87) 0.372
Readmission within 90 days, n (%) 53 (17) 6 (17) 59 (17) 0.908
Postoperative morbidity, n (%) 185 (60) 25 (64) 210 (61) 0.664
Major postoperative morbidity, n (%) 73 (24) 12 (31) 85 (25) 0.339
Postoperative mortality, n (%) 6 (2.0) 6 (15.4) 12 (3.5) <0.0001
POPF, n (%) 0.035
None 221 (72) 31 (79) 252 (73)
Type A 43 (14) 3 (8) 46 (13)
Type B 9 (28) 0 (0) 28 (8)
Type C 15 (5) 5 (13) 20 (6)
Re-operation, n (%) 42 (14) 9 (23) 51 (15) 0.119
Postoperative hemorrhage, n (%) 15 (5) 7 (18) 22 (6) 0.002
Wound infection, n (%) 60 (20) 8 (21) 68 (20) 0.886
Pulmonary complication, n (%) 34 (11) 10 (26) 44 (13) 0.010
Cardiovascular complication, n (%) 15 (5) 8 (21) 23 (7) <0.0001
Renal complication, n (%) 15 (5) 3 (8) 18 (5) 0.457
BMI, body mass index; ASA, American Society of Anesthesiologists; POPF, postoperative pancreatic fistula; ICU, intensive care unit; PDAC,
pancreatic ductal adenocarcinoma.
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3.2. Comparison of Patients Undergoing Pancreaticoduodenectomy
In Table 2, data is focusing on the PD, as it is the most challenging of pancreatic
resections. PD was performed in 185 patients during the study period, and 26 patients
(14%) were ≥80 years old. Postoperative mortality was higher in the ≥80 years old group
(11.5% vs. 1.3%, p = 0.003). There were also more POPF type C, postoperative hemorrhage,
and cardiovascular complications in the ≥80 years old group.
Table 2. Comparison of clinicopathological characteristics of 185 patients undergoing pancreatoduodenectomy according to
patient age.




(n = 185) p Value
Gender, n (%) 0.032
Female 74 (47) 18 (69) 92 (50)
Male 85 (53) 8 (31) 93 (50)
Cost recovery, %, median (range) 105 (42–233) 91 (46–172) 102 (42–233) 0.045
Heart disease, n (%) 82 (52) 23 (89) 106 (57) <0.0001
Kidney disease, n (%) 21 (13) 8 (31) 29 (16) 0.022
Smoking, n (%) 58 (37) 1 (4) 59 (32) 0.001
Alcohol consumption, n (%) 54 (34) 2 (8) 56 (30) 0.007
ASA status, n (%) 0.123
1 1 (1) 0 (0) 1 (1)
2 49 (31) 3 (12) 52 (28)
3 102 (64) 20 (77) 122 (66)
4 7 (4) 3 (11) 10 (5)
Diameter pancreatic duct, mm, median (range) 4 (1–15) 4 (3–8) 4 (1–15) 0.080
Pancreatic stent intraoperative, n (%) 37 (24) 1 (4) 28 (21) 0.021
Histologic type, n (%) 0.603
Adenocarcinoma 83 (52) 15 (58) 98 (53)
other 76 (48) 11 (42) 87 (47)
Length of ICU stay, days, median (range) 1 (0–26) 1 (1–11) 1 (0–26) 0.190
Length of hospital stay, days, median (range) 13 (7–67) 13 (3–48) 13 (3–67) 0.973
Readmission within 90 days, n (%) 26 (17) 5 (20) 31 (17) 0.661
Postoperative morbidity, n (%) 86 (54) 19 (73) 105 (57) 0.07
Major postoperative morbidity, n (%) 36 (23) 9 (35) 45 (24) 0.187
Postoperative mortality, n (%) 2 (1.3) 3 (11.5) 5 (2.7) 0.003
POPF, n (%) 0.452
None 123 (77) 20 (77) 143 (77)
Type A 12 (8) 2 (8) 14 (8)
Type B 10 (6) 0 (0) 10 (5)
Type C 14 (9) 4 (15) 18 (10)
Re-operation, n (%) 24 (15) 7 (27) 31 (17) 0.134
Salvage pancreatectomy, n (%) 13 (8) 4 (15) 17 (9) 0.432
Bile leak, n (%) 4 (3) 0 (0) 4 (2) 0.414
Gastrointestinal leak, n (%) 2 (1) 0 (0) 2 (1) 0.565
Postoperative hemorrhage, n (%) 7 (4) 5 (19) 12 (7) 0.004
Wound infection, n (%) 34 (21) 7 (27) 41 (22) 0.528
Pulmonary complication, n (%) 20 (13) 6 (23) 26 (14) 0.153
Cardiovascular complication, n (%) 6 (4) 6 (23) 12 (7) <0.0001
Renal complication, n (%) 4 (3) 2 (8) 6 (3) 0.167
BMI, body mass index; ASA, American Society of Anesthesiologists; POPF, postoperative pancreatic fistula; ICU, intensive care unit.
3.3. Comparison of Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma
In Table 3, the focus is on patients suffering from PDAC. This group consisted of
150 patients, and 25 patients (17%) were ≥80 years old. Postoperative mortality was higher
among patients ≥80 years old (n = 5 vs. n = 3, p < 0.0001). TNM stage and resection margins
status were comparable in the two groups. However, the proportion of patients ≥80 years
old who received adjuvant chemotherapy was significantly lower in comparison to the
<80 years cohort (48% vs. 79%, p = 0.001).
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Table 3. Comparison of clinicopathological characteristics of 150 patients undergoing resection for pancreatic ductal
adenocarcinoma according to patient age.




(n = 150) p Value
Gender, n (%) 0.306
Female 56 (45) 14 (56) 70 (47)
Male 69 (55) 11 (44) 80 (53)
Cost recovery, %, median (range) 103 (47–233) 90 (46–172) 100 (46–233) 0.021
Heart disease, n (%) 72 (58) 21 (84) 93 (62) 0.13
Kidney disease, n (%) 18 (14) 9 (36) 27 (18) 0.010
Smoking, n (%) 48 (38) 3 (12) 51 (34) 0.011
Alcohol consumption, n (%) 42 (34) 5 (20) 47 (31) 0.181
ASA status, n (%) 0.037
1 2 (2) 0 (0) 2 (1)
2 33 (26) 1 (4) 34 (23)
3 80 (64) 19 (76) 99 (66)
4 10 (8) 5 (20) 15 (10)
CA 19-9 preoperative, kU/L, median (range) 360 (2–63690) 311 (4–11184) 343 (2–63690) 0.692
IRE, n (%) 20 (16) 2 (8) 22 (15) 0.302
Operating time, h, median (range) 6.0 (2–9) 6.4 (4–9) 6.0 (2–9) 0.484
T stage, n (%) 0.065
T1 5 (4) 0 (0) 5 (3)
T2 45 (36) 16 (64) 61 (41)
T3 74 (59) 9 (36) 83 (55)
T4 1 (1) 0 (0) 1 (1)
N stage, n (%) 0.221
N0 22 (18) 8 (32) 30 (20)
N1 74 (59) 11 (44) 85 (57)
N3 29 (23) 6 (24) 35 (23)





Lymphagiosis carcinomatosa, n (%) 25 (20) 32 (8) 33 (22) 0.186
Venous invasion, n (%) 16 (13) 7 (28) 23 (15) 0.054
Perineural invasion, n (%) 6 (5) 2 (8) 8 (5) 0.516
Tumor differentiation, n (%) 0.484
G1 18 (14) 3 (12) 21 (14)
G2 50 (40) 14 (56) 64 (43)
G3 55 (44) 8 (32) 63 (42)
G4 2 (2) 0 (0) 2 (1)
Tumor margins, n (%) 1.0
R1 40 (32) 8 (32) 48 (32)
R0 85 (68) 17 (68) 102 (68)
Length of ICU stay, days, median (range) 1 (0–37) 1 (1–19) 1 (0–37) 0.269
Length of hospital stay, days, median (range) 13 (2–70) 12 (3–66) 13 (2–70) 0.667
Readmission within 90 days, n (%) 22 (18) 3 (13) 25 (17) 0.571
Postoperative morbidity, n (%) 70 (56) 15 (60) 86 (57) 0.713
Major postoperative morbidity, n (%) 25 (20) 8 (32) 33 (22) 0.186
Postoperative mortality, n (%) 3 (2.4) 5 (20) 8 (5.3) <0.0001
POPF, n (%) 0.077
None 104 (83) 21 (84) 125 (83)
Type A 10 (8) 1 (4) 11 (7)
Type B 8 (7) 0 (0) 8 (6)
Type C 3 (2) 3 (12) 6 (4)
Re-operation, n (%) 17 (13) 7 (28) 24 (16) 0.073
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Table 3. Cont.




(n = 150) p Value
Postoperative hemorrhage, n (%) 6 (5) 6 (24) 12 (8) 0.001
Wound infection, n (%) 30 (24) 4 (16) 34 (23) 0.383
Pulmonary complication, n (%) 16 (13) 6 (24) 22 (15) 0.148
Cardiovascular complication, n (%) 7 (6) 5 (20) 12 (8) 0.015
Renal complication, n (%) 9 (7) 2 (8) 11 (7) 0.889
Neoadjuvant chemotherapy, n (%) 13 (10) 0 (0) 13 (9) 0.092
Adjuvant chemotherapy, n (%) 99 (79) 12 (48) 111 (74) 0.001
Adjuvant radiotherapy, n (%) 1 (1) 0 (0) 1 (1) 0.654
BMI, body mass index; ASA, American Society of Anesthesiologists; IRE, Irreversible electroporation; POPF, postoperative pancreatic
fistula; ICU, intensive care unit.
3.4. Factors Associated with Postoperative Mortality
Table 4 summarizes the results of the univariate and multivariate analysis of factors
associated with 90-day postoperative mortality. Multivariate logistic regression analysis
showed that patient age ≥80 years was associated with postoperative mortality, indepen-
dently of the tumor entity and surgical technique (p = 0.013, OR 6.71, 95% confidence
interval (CI) (1.5–30.3)). Other predictive factors for postoperative mortality were post-
operative hemorrhage (p = 0.001, OR 12.21 95% CI (2.7–55.9)), and renal complications
(p = 0.001, OR 15.80, 95% CI (3.1–81.4)). Table 5 provides detailed information on the
six patients ≥80 years old suffering postoperative 90-day mortality following pancreatic
surgery, including postoperative complications and cause of death. Among the six octo-
genarians who died after pancreatic surgery, three patients suffered POPF type C, and
four patients required re-operation because of postoperative hemorrhage. In this group
of postoperative mortality, three patients underwent a Whipple procedure, but only two
of them suffered POPF. One patient had a soft pancreatic texture, and the other one hard
pancreatic texture. Additional to the surgical complications, the cause of death in three
patients included respiratory failure (due to aspiration pneumonia), cardiac arrest (due to
myocardial infarction), and liver failure (due to thrombosis of the common hepatic artery),
respectively (Table 5).









(n = 346) p Value
MV
p Value, OR (CI)
Male, n (%) 7 (58) 177 (53) 184 (53) 0.716
Age ≥80 years, n (%) 6 (50) 33 (10) 39 (11) <0.0001 0.013,6.71 (1.5–30.3)
Heart disease, n (%) 8 (67) 182 (55) 190 (55) 0.411
Kidney disease, n (%) 2 (17) 52 (16) 54 (16) 0.918
Pulmonary disease, n (%) 5 (42) 74 (22) 79 (23) 0.114
Alcohol consumption, n (%) 2 (17) 110 (33) 112 (32) 0.237
ASA status 4, n (%) 1 (8) 16 (5) 7 (6) 0.577
Resection type, n (%) 0.295
Pancreatoduodenectomy 5 (42) 180 (54) 185 (53)
Distal pancreatectomy 3 (25) 66 (20) 69 (20)
Total pancreatectomy 4 (33) 41 (12) 45 (13)
Enucleation 0 (0) 3 (1) 3 (1)
Duodenal-preserving resection 0 (0) 24 (7) 24 (7)
Segmental pancreatic resection 0 (0) 20 (6) 20 (6)










(n = 346) p Value
MV
p Value, OR (CI)
Histologic type, n (%) 0.097
Adenocarcinoma 8 (67) 142 (43) 150 (43)
other 4 (33) 192 (56) 196 (57)
Vascular reconstruction, n (%) 0.001 NS
none 4 (34) 264 (79) 268 (78)
venous 6 (50) 60 (18) 66 (19)
arterial 1 (8) 7 (2) 8 (2)
combined 1 (8) 3 (1) 4 (1)
POPF, n (%) 0.036 NS
None 7 (59) 245 (73) 252 (73)
Type A 1 (8) 45 (14) 46 (13)
Type B 1 (8) 27 (8) 28 (8)
Type C 3 (25) 17 (5) 20 (6)
Postoperative hemorrhage, n (%) 6 (50) 16 (5) 22 (6) <0.0001 0.001,12.21 (2.7–55.9)
Wound infection, n (%) 3 (25) 65 (20) 68 (20) 0.635
Pulmonary complication, n (%) 6 (50) 38 (11) 44 (13) <0.0001 NS
Cardiovascular complication, n (%) 5 (42) 18 (5) 23 (7) <0.0001 NS
Renal complication, n (%) 6 (50) 12 (4) 18 (5) <0.0001 0.001,15.80 (3.1–81.4)
BMI, body mass index; ASA, American Society of Anesthesiologists; MV, multivariate logistic regression analysis; OR, odds ratio; CI,
confidence interval; NS, not significant; POPF, postoperative pancreatic fistula.
Table 5. Clinicopathological characteristics of the six patients ≥80 years old suffering postoperative 90-day mortality
following pancreatic surgery.
Variable Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Gender Male Male Female Male Female Female
Age 81 85 80 82 81 84
Comorbidities no cardiac cardiac cardiac renal cardiac
ASA status 2 3 3 3 3 3



















Pancreas texture soft soft hard soft hard soft
Pancreatic duct
diameter (mm) - - 8 3 4 -
POPF type A type C no type C type C no
Postoperative
hemorrhage no yes yes yes no yes



















ICU stay, days 8 19 3 4 7 11
Postoperative day
of death 18 67 3 22 11 52
Cause of death cardiac arrest sepsis liver failure respiratory failure sepsis sepsis
ASA, American Society of Anesthesiologists; POPF, postoperative pancreatic fistula; ICU, intensive care unit.
J. Clin. Med. 2021, 10, 696 10 of 15
3.5. Long-Term Survival of Patients with PDAC
Among patients with PDAC, patient age was not associated with oncologic outcome
using a cut-off value of 80 years. Three-year overall survival rates were comparable between
patients <80 years old and patients ≥80 years old (42.4% vs. 41.9%, p = 0.059, Figure 1).
The median survival was 24 (18–30) months for patients <80 years old vs. 13 (6–20) months
for patients ≥80 years old (p = 0.059).
We analyzed the impact of sex on OS in the subgroups of patients <80 years old and
patients ≥80 years old. We found no statistically significant survival difference between
female and male patients, both in patients <80 years old (female, n = 56, 3-year OS 45%
vs. male, n = 68, 3-year OS 40.8%, p = 0.638) and patients ≥80 years old (female, n = 14,
3-year OS 51.6% vs. male, n = 11, 3-year OS 31.8%, p = 0.571), even though OS was higher
for female patients in both groups.




Figure 1. Comparison of overall survival (OS) in patients with pancreatic ductal adenocarcinoma (n = 150) according to 
patient age (<80 years vs. ≥80 years). 
4. Discussion 
In an unselected group of 346 consecutive patients, our study examined the impact 
of patient age on postoperative mortality and morbidity after pancreatic resective surgery. 
Importantly, we focused not only on the entire cohort, but also on the group of patients 
undergoing PD and on those suffering from PDAC. 
Patient age ≥80 years was significantly associated with a higher rate of both surgical 
and medical complications in our study. Additionally, the postoperative mortality rate 
was higher in our cohort of patients ≥80 years old. These results are comparable to those 
of previous studies, including a large study from Germany, investigating the results of 
1705 pancreatic operations, including 76 (4.5%) patients ≥80 years old [8]. A recent inter-
national multicentric study with 3624 elderly patients from Belgium, the Netherlands, and 
Norway showed postoperative mortality rates beyond 10% for patients ≥80 years old, un-
derlining the importance of investigating the role of patient age on outcomes following 
pancreatic surgery [15]. The aim of this study was not to determine a cut-off age for pan-
creatic surgery, but to underline the importance of correct identification of the candidates 
who will benefit from surgery the most, despite advanced age. Elderly patients are more 
fragile and have fewer capacities to overcome major postoperative complications [29]. 
A higher rate of medical complications, such as pneumonia and cardiovascular ad-
verse events, has been found in the cohort of patients ≥80 years old in our study. Elderly 
patients presented more frequently with preoperative cardiovascular and pulmonary 
comorbidities, which may have deteriorated postoperatively. The association between rel-
evant comorbidities and increased postoperative complications has been previously dis-
cussed [30]. In this regard, frailty among elderly patients is known as a state of decreased 
capacity to cope with stress factors in order to restore homeostasis [1]. However, frailty is 
an independent factor that does not always correlate with age and may also be reversible 
[31]. Our results, indicating that the elderly population is more vulnerable to postopera-
tive complications with a lower capacity to recover, underline the need for precise pre-
operative assessment of medical preconditions in order to improve patient selection and 
reduce the risk for selected patients. Patient-level factors contributed the most to the in-
creased risk of mortality after PD in a recent US study [32]. Additionally, interventions 
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4. Discussion
In an unselected group of 346 consecutive patients, our study examined the impact of
patient age on postoperative mortality and morbidity after pancreatic resective surgery.
Importantly, we focused not only on the entire cohort, but also on the group of patients
undergoing PD and on those suffering from PDAC.
Patient age ≥80 years was significantly associated with a higher rate of both surgical
and medical complications in our st dy. Additionally, the postoperative mortality rate
was higher in our cohort of patients ≥80 years old. These results are comparable to those
of previous studies, including a large study from Germany, investigating the results of
1705 pancreatic operations, including 76 (4.5%) patients ≥80 years old [8]. A recent in-
ternational multicentric study with 3624 elderly patients from Belgium, the Netherlands,
and Norway showe postoperative mortality rates be ond 10% fo patients ≥80 years old,
underlining the importance of investigating the role of patient age on outcomes following
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pancreatic surgery [15]. The aim of this study was not to determine a cut-off age for pan-
creatic surgery, but to underline the importance of correct identification of the candidates
who will benefit from surgery the most, despite advanced age. Elderly patients are more
fragile and have fewer capacities to overcome major postoperative complications [29].
A higher rate of medical complications, such as pneumonia and cardiovascular ad-
verse events, has been found in the cohort of patients ≥80 years old in our study. Elderly
patients presented more frequently with preoperative cardiovascular and pulmonary
comorbidities, which may have deteriorated postoperatively. The association between
relevant comorbidities and increased postoperative complications has been previously dis-
cussed [30]. In this regard, frailty among elderly patients is known as a state of decreased
capacity to cope with stress factors in order to restore homeostasis [1]. However, frailty is an
independent factor that does not always correlate with age and may also be reversible [31].
Our results, indicating that the elderly population is more vulnerable to postoperative
complications with a lower capacity to recover, underline the need for precise preoperative
assessment of medical preconditions in order to improve patient selection and reduce the
risk for selected patients. Patient-level factors contributed the most to the increased risk of
mortality after PD in a recent US study [32]. Additionally, interventions must be under-
taken prior to surgery to improve nutritional status [20], and the medical comorbidities,
when possible. It is important to mention that we have conducted even more extensive
conversations with the older patients, mostly together with their families, in order to find
out how their physical capacity in daily life was and how much treatment they wished to
undergo. Based on the results of our study showing that patient age is a prognostic factor
for adverse events after surgery, elderly patients and their close family members were made
aware of this risk during preoperative counseling. They were explicitly informed of the
possible need for prolonged intensive care, respiratory, cardiovascular, and renal support,
in the case of a complication. If, during the preoperative counseling, life-support measures
were denied by the patient in the case of a postoperative complication, the indication for
major resection was restricted.
ASA status has been identified as a useful tool for preoperative assessment [33]. We
showed that the group of patients ≥80 years old had mostly higher ASA scores, however
ASA status of 4 was not associated with higher postoperative mortality in our study.
Nevertheless, this result may be associated with the low number of ASA 4 patients, and
octogenarians with an ASA status 4 are not considered as surgical candidates in our
practice anymore.
Patients ≥80 years old suffered more frequently from POPF type C with subsequent
hemorrhage [34]. Increased patient age is only one factor among others, such as BMI,
visceral fat thickness, pancreatic duct size, and pancreas tissue texture that have been
previously shown to be associated with POPF [35–37]. Thus, postoperative hemorrhage,
due to vessel erosion, may have been responsible for the increased postoperative mortality
in the octogenarian cohort, additionally to the increased preoperative risk factors. Patient
age ≥80 years was associated with postoperative mortality in the entire cohort, as well as
in the subset of patients undergoing pancreaticoduodenectomy, and patients with PDAC.
Postoperative mortality among octogenarians was even higher in patients with PDAC
compared to other indications for pancreatic surgery. This difference may be explained by
the fact that oncological patients often present with more severe malnutrition and have
less capacity to recover [38]. Moreover, even though not statistically significant, there was
a trend to more total pancreatectomies among octogenarians. This is in concordance with
previous studies as total pancreatectomy is often favored over a partial pancreaticoduo-
denectomy in high-risk patients with more advanced disease [39]. Nevertheless, patient
age was associated with postoperative mortality independently of the tumor entity and
surgical technique in the multivariate analysis. However, the large confidence interval
(1.5–30.3) for postoperative mortality in the multivariate analysis indicates the relatively
small number of patients involved.
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Cost recovery following pancreatic resection was worse for patients ≥80 years old in
the entire cohort, as well as in patients with PDAC and patients undergoing PD. Higher
surgical (POPF, hemorrhage) and medical (pulmonary, cardiovascular) postoperative com-
plications in this cohort have contributed to higher treatment costs, and thus, worse
financial balance. Previous studies confirmed that higher costs are directly related to the
presence of severe complications and longer hospital stay [17]. Grade III and IV complica-
tions cause a doubling of the costs compared to an uneventful postoperative course [17].
Nevertheless, financial criteria and potentially worse cost recovery after surgery are cur-
rently not taken into consideration, when evaluating octogenarians or any other patient
cohort for pancreatic resection or other oncologic treatment.
In our study, we have observed that the older population was less likely to receive
adjuvant chemotherapy. Postoperative complications (especially pancreatic fistula and
postoperative hemorrhage), but also higher age, and lower center volume were predictive
factors for not receiving adjuvant chemotherapy after pancreatic resection in a recent Dutch
multicentric study [40]. In our cohort, this result can be explained by higher rates of
POPF and postoperative hemorrhage among patients ≥80 years old. Additionally, a large
proportion of our patients undergoes systemic treatment in peripheral hospitals, where
older patients are often treated less aggressively, and higher dropout rates during adjuvant
chemotherapy are observed [41]. In our center, we have been increasingly recommending
neoadjuvant chemotherapy for 3–6 months for patients with borderline resectable or locally-
advanced PDAC in the most recent years. Among 150 patients with PDAC, only 13 patients
<80 years were administered preoperative chemotherapy in our study. Due to our relatively
strict selection criteria for pancreatic surgery among elderly patients, patients ≥80 years
old with such extended tumor burden requiring long preoperative chemotherapy and
complex surgery were mostly not appropriate surgical candidates. Additionally, elderly
patients ≥80 years old often did not qualify for the preferred regimen with FOLFIRINOX,
which has a relevant toxicity profile, as indicated by the study from Conroy et al., which
included only patients <80 years in the FOLFIRINOX arm [42].
Our survival analysis for patients with PDAC showed that patient age was not signifi-
cantly associated with oncologic outcome. Although, mortality has been more frequently
observed among patients ≥80 years old in the first two years following oncologic resection,
survival did not differ between the two groups on the long-term and 3-year OS was identi-
cal (<80 years: 42.4% vs. ≥80 years: 41.9%, p = 0.059). This result indicates that prolonged
survival is possible for well-selected patients ≥80 years old, who undergo oncologic re-
section with an uneventful postoperative course, enhanced recovery, and fast return to
normal function.
Finally, our study has several limitations. It is a retrospective analysis of an inho-
mogeneous population of patients, including benign and malignant pancreatic lesions.
However, it represents the standard case profile of a high-volume center in Switzerland,
reflecting our experience with an octogenarian population. We have performed analysis
using the cut-off age of 80 years, acknowledging that results may slightly vary by choosing
another value. However, our aim was not to provide evidence on whether to operate on
patients ≥80 years old or not, but rather to indicate the challenges older and multimorbid
patients requiring pancreatic surgery provide and to discuss ways to improve outcomes in
this cohort.
5. Conclusions
Patient age of ≥80 years was associated with a higher risk for medical and surgical
postoperative complications and mortality following pancreatic surgery. Reduced capacity
for successful resuscitation and postoperative recovery when requiring revision surgery
among the elderly patient cohort has been identified. Surgical treatment of octogenarians
was also related to a lower cost recovery rate. Nevertheless, pancreatic surgery remains
the only curative-intended approach for pancreatic cancer, and therefore, careful patient
selection is essential to achieve favorable outcomes.
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